Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI ranks Bionano Genomics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Bionano Genomics, Inc. is a small-cap company with a market capitalization of $16M. It ranks number 22 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for BNGO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BNGO included.
Follow BNGO free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
| Metric | BNGO | Rank |
|---|---|---|
| Market Cap | $16M | 22/25 |
| P/B Ratio | 0.50x | 22/23 |
| EPS | $-2.35 | – |
| Book Value/Share | $2.68 | – |
| Revenue/Share | $2.56 | – |
| Metric | BNGO | Rank |
|---|---|---|
| ROE | -101.8% | 19/21 |
| ROA | -67.6% | 19/22 |
| ROIC | -85.7% | 18/21 |
| Gross Margin | 47.5% | 10/19 |
| Operating Margin | -106.7% | 16/21 |
| Net Margin | -106.6% | 16/20 |
| EBT Margin | -106.4% | 18/22 |
| Tax Rate | -0.2% | – |
| Metric | BNGO | Rank |
|---|---|---|
| Current Ratio | 2.48x | 16/25 |
| Quick Ratio | 1.78x | 13/24 |
| D/E Ratio | 0.51x | 12/24 |
| Financial Leverage | 1.51x | 12/24 |
| Interest Coverage | -29.5x | 14/21 |
| Working Capital | $15M | 20/25 |
| Metric | BNGO | Rank |
|---|---|---|
| Operating Cash Flow | -$20M | 18/24 |
| Metric | BNGO | Rank |
|---|---|---|
| Asset Turnover | 0.63x | 6/21 |
| Receivables Turnover | 6.9x | 4/19 |
| Inventory Turnover | 2.3x | 8/19 |
| Fixed Assets Turnover | 2.3x | 19/21 |
| Days Sales Outstanding | 53 days | 16/19 |
| Days Inventory | 162 days | 12/19 |
| Payables Period | 105 days | 2/18 |
| Cash Conversion Cycle | 109 days | 13/17 |
| Metric | BNGO | Rank |
|---|---|---|
| Total Revenue | $30M | 16/21 |
| Operating Income | -$32M | 12/21 |
| Net Income | -$32M | 11/22 |
| R&D Expense | $12M | 17/21 |
| SG&A Expense | $34M | 18/20 |
| Cost of Goods Sold | $16M | 14/19 |
| Metric | BNGO | Rank |
|---|---|---|
| Shares Outstanding | 12M | – |
| Total Current Assets | $25M | 52.3% of assets |
| Cash & Short-term Investments | $4M | 7.8% of assets |
| Accounts Receivable | $4M | 9.2% of assets |
| Inventory | $7M | 14.7% of assets |
| Total Liabilities | $16M | 33.6% of assets |
| Short-term Debt | $5M | 11.5% of assets |
Companies classified under the same SEC industry code as Bionano Genomics, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| BNGO Bionano Genomics, Inc. | ▲ | $16M |
| A Agilent Technologies, Inc. | ▼ | $48.40B |
| WAT Waters Corp /De/ | ▲ | $42.45B |
| ILMN Illumina, Inc. | ▶ | $40.95B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.02B |
| RVTY Revvity, Inc. | ▼ | $17.30B |
| AVTR Avantor, Inc. | ▶ | $10.62B |
| BIO Bio-Rad Laboratories, Inc. | ▼ | $9.73B |
| TXG 10x Genomics, Inc. | ▲ | $9.35B |
| BRKR Bruker Corp | ▲ | $8.56B |
| ALMR Alamar Biosciences, Inc. | ▶ | $1.63B |
| CTKB Cytek Biosciences, Inc. | ▲ | $695M |
| PACB Pacific Biosciences Of California, Inc. | ▲ | $637M |
| MASS 908 Devices Inc. | ▲ | $500M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $275M |
| EYPT Eyepoint, Inc. | ▲ | $265M |
| NAUT Nautilus Biotechnology, Inc. | ▲ | $261M |
| QTRX Quanterix Corp | ▲ | $149M |
| SEER Seer, Inc. | ▶ | $119M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $44M |
| PRPO Precipio, Inc. | ▲ | $40M |
| HBIO Harvard Bioscience Inc | ▼ | $38M |
| LCTC Lifeloc Technologies, Inc | ▲ | $11M |
| ASTC Astrotech Corp | ▶ | $11M |
| SCND Scientific Industries Inc | ▲ | $8M |
This article first appeared on GuruFocus. Bionano Genomics Inc (NASDAQ:BNGO) is set to release its Q1 2026 earnings on May 13, 2026. The consensus estimate for Q1 2026 revenue is $6.57 million, and ...
Shares of Bionano Genomics Inc. BNGO are trading sharply higher Tuesday afternoon, expanding multi-session upside as investors digest management’s multi-year growth strategy delivered at a major ...
Good day, and welcome to the Bionano Second Quarter 2026 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from ...
Our AI ranks Bionano Genomics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
A per-ticker accuracy statistic for BNGO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Bionano Genomics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
25 issuers in our coverage, BNGO included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.